Monoclonal Antibodies Market to amass over US $148.9 BN by 2026

June 11, 2019


Worldwide Monoclonal Antibodies (mAbs) Market is estimated to accumulate over US $148.9 billion by the year 2026, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2026.
 

The global monoclonal antibodies market is primarily driven by an active pipeline of numerous monoclonal antibodies at different stages of drug development. Other significant factors propelling the growth of the global market include growing research & development, increasing incidences of cancer and other chronic diseases, favorable government policies, higher demand for personalized medicine, and surging awareness among medical professionals and patients regarding the latest medical therapies. Also, price correction, central nervous system disorders, and new delivery strategies for monoclonal antibodies, are said to offer growth prospects to the market worldwide in the coming years.
 

Monoclonal antibodies form a major part of the pharmaceutical market, with many of these are still in the pipeline. Several monoclonal antibodies are in the pipeline, at the pre-clinical as well as at various other stages of clinical trials, with more than 30 monoclonal antibodies approved by regulatory authorities for use. Moreover, availability of advanced technology for the production of monoclonal antibodies has encouraged a number of market players to create their own pipelines. The patents of several monoclonal antibodies have expired in the past few years, which has encouraged other pharmaceutical companies to produce monoclonal antibodies.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1700727/
 

According to the findings of the report, the research & development activities have increased in the field of monoclonal antibodies. Technological and biomedical advancements in genetic engineering, next-generation genome sequencing, and favorable government initiatives are expected to push the market growth. Market specialists claim that pre-defined guidelines by the regulatory authorities would ensure effective, safe, and high-quality manufacturing of the monoclonal antibodies. For instance, the European Commission recently approved the first biosimilar mAb – Celltrion’s Truxima.
 

The rising demand for personalized medicine plays a pivotal part in bolstering the mAbs market by pushing the development of personalized drug targets, since each patient responds in a different manner to different treatments. Other factors such as homogeneity, specificity, and relatively fewer adverse events with personalized medicine usage also contribute to market growth.
 

The report cites that several mAbs used in the treatment of fatal infections, like HIV/AIDS, Ebola, and Zika viral diseases, are currently under different phases of clinical trials. Furthermore, high spending capability of patients in the developed countries, rising disposable incomes, improved healthcare facilities, ascending awareness about the latest medical therapies, and growing utilization of mAbs in treatment regimens are expected to supplement the global mAbs market growth.
 

Based on the product landscape, the monoclonal antibodies market has been bifurcated into fully human, chimeric, murine, and humanized antibodies. In the year 2017, the fully human monoclonal antibodies segment bagged a major share in the global market. On the basis of indication, the global market is bifurcated into cancer, cardiovascular diseases, inflammation, transplant rejection, respiratory, and infectious diseases.
 

The cancer segment reportedly led the global market in the year 2017, in terms of revenue, and is anticipated to become the leading revenue contributor over the forecast timeframe. The segmental contribution can be credited to the rapidly expanding patient pool, improving medical facilities, rising disposable incomes in emerging nations, and high spending capacity in developed nations.
 

Depending on the production system the monoclonal antibodies market is divided into microbial fermentation and mammalian cell culture. While, in terms of target mechanism of action, the global mAbs market is segmented into HER2, CGRP, CTLA4, EGFR, TNF alpha, Anti CD, IgGs, VEGF, and Anti-IL.
 

The renowned companies operating in the worldwide monoclonal antibodies market include GlaxoSmithKline PLC, Pfizer Inc., Thermo Fisher Scientific Inc., Merck & Co. Inc., Hoffmann-La Roche Ltd., Novartis AG, Abbott Laboratories, AstraZeneca, Eli Lily & Co., Amgen Inc., Daiichi Sankyo Company Ltd., Bistro-Myers Squibb, Mylan N.V., Novo Nordisk A/S, and Bayer AG. These market players have adopted several strategies including new product development and release, venture capital investments, etc., to set a strong foot in the global market and enhance their customer base.